Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2569305 | 0.92 | HSD17B10 (0.35) | HSD17B10TSHRLMNA | |
| SCHEMBL1100522 | 0.74 | HSD17B10 (0.37) | HSD17B10TSHRLMNA | |
| SCHEMBL3708716 | 0.73 | HSD17B10 (0.44) | HSD17B10TSHRLMNA | |
| SCHEMBL3711848 | 0.73 | HSD17B10 (0.44) | HSD17B10TSHRLMNA | |
| SCHEMBL155553 | 0.73 | HSD17B10 (0.44) | HSD17B10TSHRLMNA | |
| SCHEMBL1565455 | 0.73 | HSD17B10 (0.44) | HSD17B10TSHRLMNA | |
| SCHEMBL2575287 | 0.72 | — | — | |
| SCHEMBL28044979 | 0.70 | HSD17B10 (0.41) | HSD17B10TSHRLMNA | |
| SCHEMBL1100545 | 0.70 | HSD17B10 (0.37) | HSD17B10TSHRLMNA | |
| SCHEMBL5572350 | 0.69 | HSD17B10 (0.48) | HSD17B10TSHRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1637526-B1 | CURABLE POLYCYCLIC COMPOUNDS AND PROCESS FOR THE PRODUCTION THEREOF | TOKUYAMA CORP (JP) | 2011-11-09 | — | — | EP | disclosed |
| US-7754903-B2 | adamantyl diglycidyl ether or 1-adamantanol epichlorohydrin adduct curable to polyepoxides; encapsulant for light-emitting diode; superior optical properties, heat resistance, photostability, and shrinkage inhibition | TOKUYAMA CORPORATION (JP) | 2010-07-13 | — | — | US | disclosed |
| US-20060252911-A1 | adamantyl diglycidyl ether or 1-adamantanol epichlorohydrin adduct curable to polyepoxides; encapsulant for light-emitting diode; superior optical properties, heat resistance, photostability, and shrinkage inhibition | TOKYUYAMA CORPORATION (JP) | 2006-11-09 | — | — | US | disclosed |
| EP-1637526-A1 | CURABLE POLYCYCLIC COMPOUNDS AND PROCESS FOR THE PRODUCTION THEREOF | TOKUYAMA CORPORATION (JP) | 2006-03-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252911-A1 | adamantyl diglycidyl ether or 1-adamantanol epichlorohydrin adduct curable to polyepoxides; encapsulant for light-emitting diode; superior optical properties, heat resistance, photostability, and shrinkage inhibition | PFN1, FSCN1, PFDN1 | HSD17B10 1998/4885TSHR 3361/4885LMNA 1430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.